

Electronic Acknowledgement Receipt

EFS ID:	6702654
Application Number:	10598295
International Application Number:	
Confirmation Number:	2459
Title of Invention:	Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
First Named Inventor/Applicant Name:	Donald W. Kufe
Customer Number:	32425
Filer:	Steven Lee Highlander/Christopher Jackson
Filer Authorized By:	Steven Lee Highlander
Attorney Docket Number:	GENU:006US/10717023
Receipt Date:	23-DEC-2009
Filing Date:	05-APR-2007
Time Stamp:	16:07:08
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$1110
RAM confirmation Number	3072
Deposit Account	501212
Authorized User	HIGHLANDER,STEVEN L.

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		GENU006US_AMEND1.pdf	5526349 8bc15dc65d00d9855a9f5a456c3a015192f96d8	yes	100
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Amendment/Req. Reconsideration-After Non-Final Reject		1		1
	Claims		2		2
	Applicant Arguments/Remarks Made in an Amendment		3		100
Warnings:					
Information:					
2	Applicant Arguments/Remarks Made in an Amendment	GENU006US_AMEND2.pdf	11714649 189497607008c1c413d3d0492a22462216d85c	no	100
Warnings:					
Information:					
3	Applicant Arguments/Remarks Made in an Amendment	GENU006US_AMEND3.pdf	8285517 0ed7c1559084cod317a8f2b064a488d0525d0	no	74
Warnings:					
Information:					
4	Extension of Time	GENU006US_EOT.pdf	62646 65390b19c6d42b49c57a70e1586432b3c115726	no	1
Warnings:					
Information:					
5	Fee Worksheet (PTO-875)	fee-info.pdf	30628 5ed808b012c0f5e0cd3f8c33d51e9a08a27b00c3	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			25619789		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.